TY - JOUR
T1 - Circulating miRNA panels for specific and early detection in bladder cancer
AU - Usuba, Wataru
AU - Urabe, Fumihiko
AU - Yamamoto, Yusuke
AU - Matsuzaki, Juntaro
AU - Sasaki, Hideo
AU - Ichikawa, Makiko
AU - Takizawa, Satoko
AU - Aoki, Yoshiaki
AU - Niida, Shumpei
AU - Kato, Ken
AU - Egawa, Shin
AU - Chikaraishi, Tatsuya
AU - Fujimoto, Hiroyuki
AU - Ochiya, Takahiro
N1 - Funding Information:
The authors thank Tomomi Fukuda, Takumi Sonoda, Hiroko Tadokoro, Megumi Miyagi, Tatsuya Suzuki and Kamakura Techno-Science for performing the microarray assays, Junpei Kawauchi and Satoshi Kondou for technical support, Noriko Abe for the management of serum samples, Michiko Ohori for the management of personal information, Hitoshi Fujimiya for developing in-house analytic tools, and Kazuki Sudo for independent confirmation of participant eligibility. Some of the samples were obtained from NCC Biobank, which is supported by NCC Research and Development Fund (29-A-1). Some clinical information was obtained from the Center for Cancer Registries, NCC. The authors also thank Biobank at the NCGG for providing biological resources.
Funding Information:
Techno-Science for performing the microarray assays, Junpei Kawauchi and Satoshi Kondou for technical support, Noriko Abe for the management of serum samples, Michiko Ohori for the management of personal information, Hitoshi Fujimiya for developing in-house analytic tools, and Kazuki Sudo for independent confirmation of participant eligibility. Some of the samples were obtained from NCC Biobank, which is supported by NCC Research and Development Fund (29-A-1). Some clinical information was obtained from the Center for Cancer Registries, NCC. The authors also thank Biobank at the NCGG for providing biological resources.
Publisher Copyright:
© 2018 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.
PY - 2019/1
Y1 - 2019/1
N2 - Bladder cancer is the 9th leading cause of cancer death worldwide. The major problem in bladder cancer is primarily the high recurrence rate after drug treatment and resection. Although conventional screening methods, such as cystoscopy, urinary cytology and ultrasound sonography, have become widely used in clinical settings, the diagnostic performance of these modalities is unsatisfactory due to low accuracy or high invasiveness. Because circulating micro RNA (miRNA) profiles have recently been reported as an attractive tool for liquid biopsy in cancer screening, here, we performed global miRNA profiling of 392 serum samples of bladder cancer patients with 100 non-cancer samples and 480 samples of other types of cancer as controls. We randomly classified the bladder cancer and control samples into 2 cohorts, a training set (N = 486) and a validation set (N = 486). By comparing both controls, we identified specific miRNA, such as miR-6087, for diagnosing bladder cancer in the training and validation sets. Furthermore, we found that a combination of 7 miRNA (7-miRNA panel: miR-6087, miR-6724-5p, miR-3960, miR-1343-5p, miR-1185-1-3p, miR-6831-5p and miR-4695-5p) could discriminate bladder cancer from non-cancer and other types of tumors with the highest accuracy (AUC:.97; sensitivity: 95%; specificity: 87%). The diagnostic accuracy was high, regardless of the stage and grade of bladder cancer. Our data demonstrated that the 7-miRNA panel could be a biomarker for the specific and early detection of bladder cancer.
AB - Bladder cancer is the 9th leading cause of cancer death worldwide. The major problem in bladder cancer is primarily the high recurrence rate after drug treatment and resection. Although conventional screening methods, such as cystoscopy, urinary cytology and ultrasound sonography, have become widely used in clinical settings, the diagnostic performance of these modalities is unsatisfactory due to low accuracy or high invasiveness. Because circulating micro RNA (miRNA) profiles have recently been reported as an attractive tool for liquid biopsy in cancer screening, here, we performed global miRNA profiling of 392 serum samples of bladder cancer patients with 100 non-cancer samples and 480 samples of other types of cancer as controls. We randomly classified the bladder cancer and control samples into 2 cohorts, a training set (N = 486) and a validation set (N = 486). By comparing both controls, we identified specific miRNA, such as miR-6087, for diagnosing bladder cancer in the training and validation sets. Furthermore, we found that a combination of 7 miRNA (7-miRNA panel: miR-6087, miR-6724-5p, miR-3960, miR-1343-5p, miR-1185-1-3p, miR-6831-5p and miR-4695-5p) could discriminate bladder cancer from non-cancer and other types of tumors with the highest accuracy (AUC:.97; sensitivity: 95%; specificity: 87%). The diagnostic accuracy was high, regardless of the stage and grade of bladder cancer. Our data demonstrated that the 7-miRNA panel could be a biomarker for the specific and early detection of bladder cancer.
KW - bladder cancer
KW - circulating microRNA
KW - diagnosis
KW - early detection
KW - liquid biopsy
UR - http://www.scopus.com/inward/record.url?scp=85059465771&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85059465771&partnerID=8YFLogxK
U2 - 10.1111/cas.13856
DO - 10.1111/cas.13856
M3 - Article
C2 - 30382619
AN - SCOPUS:85059465771
SN - 1347-9032
VL - 110
SP - 408
EP - 419
JO - Cancer science
JF - Cancer science
IS - 1
ER -
